Showing 3011-3020 of 3415 results for "".
- FDA Accepts Revance's BLA Resubmission for DaxibotulinumtoxinAhttps://practicaldermatology.com/news/fda-accepts-revances-bla-resubmission-for-daxibotulinumtoxina/2461167/The U.S. Food and Drug Administration (FDA) accepted Revance’s Biologics License Application (BLA) resubmission for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines. The FDA designated the BLA as a Class 2 resubmission, which has a six-mont
- FDA Cracks Down on OTC HQ Productshttps://practicaldermatology.com/news/fda-cracks-down-on-otc-hq-products/2461164/The US Food and Drug Administration is cracking down on over-the-counter (OTC) skin lightening products containing hydroquinone (HQ) that do not meet the requirements to be legally sold as OTC drugs. The group issued warning letters to 12 companies explaining that all OTC skin lightenin
- Botox Cosmetic Turns 20!https://practicaldermatology.com/news/botox-cosmetic-turns-20/2461158/Allergan Aesthetics’ BOTOX Cosmetic (onabotulinumtoxinA) turns 20 on April 15, 2022. This date marks 20 years since the U.S. Food and Drug Administration (FDA) first approved the product to temporarily improve the look of moderate to severe glabellar lines, located between th
- Bill Scott Named President of Endymed's US Subsidiaryhttps://practicaldermatology.com/news/bill-scott-named-president-of-endymeds-us-subsidiary/2461151/Bill Scott is the new president of Endymed Ltd’s US subsidiary, Endymed Inc. Mr. Scott will be responsible for leading Endymed's sales teams in the United States. The Company believes that the joining of Mr. Scott will drive its US growth plan and help secure a signi
- Aquavit Submits NDA for New Neurotoxinhttps://practicaldermatology.com/news/aquavit-submits-nda-for-new-neurotoxin/2461141/Aquavit Pharmaceuticals, Inc. has submitted its IND for a new botulinum toxin (DTX-021) to the FDA for approval. The company also unveiled its development programs at the Annual meeting of the American Academy of Dermatology in Boston. DTX-021, a botulinum toxin type A drug intende
- DERMWIRE Exclusive: FDA Clears Cutera’s AviClear Acne Devicehttps://practicaldermatology.com/news/dermwire-exclusive-fda-clears-cuteras-aviclear-acne-device/2461124/The U.S. Food and Drug Administration has cleared granted 510(k) clearance to Cutera’s AviClear acne device. This is the first energy device to receive a nod for the treatment of mild, moderate, and severe acne. AviClear targets acne at the source by selec
- Meet the Winners of the BTL Cares Scholarship Programhttps://practicaldermatology.com/news/meet-the-winners-of-the-btl-cares-scholarship-program/2461092/BTL and professional basketball player Andre Drummond have selected the five winners of their first-ever scholarship program – the BTL Scholar Draft. The program awarded each of the five students a $15,000 grant towards tuition and college fees. The
- AbbVie, University of Toronto Establish Endowed Chair in Ethnodermatologyhttps://practicaldermatology.com/news/abbvie-university-of-toronto-establish-endowed-chair-in-ethnodermatology/2461081/AbbVie donated CDN $3M to establish an AbbVie Chair in Ethnodermatology at the University of Toronto’s Temerty Faculty of Medicine. One of the first positions of its kind in the world, the Chair will drive collaborative academic research, provide advanc
- FDA Green-lights Casio’s DZ-D100 Dermocamera and the DZ-S50 Scopehttps://practicaldermatology.com/news/fda-green-lights-casios-dz-d100-dermocamera-and-the-dz-s50-scope/2461076/The U.S. Food and Drug Administration (FDA) has cleared Casio’s
- Juvederm Volbella XC Scores FDA Nod for Undereye Hollowshttps://practicaldermatology.com/news/juvederm-volbella-xc-scores-fda-nod-for-undereye-hollows/2461071/The US Food and Drug Administration has given its nod to Allergan Aesthetics, Juvederm Volbella XC for improvement of infraorbital hollows in adults over the age of 21. Per FDA requirement for this new indication, Allergan Aesthetics is providing a product training